Profile
| Metric | Value |
|---|---|
| Full Name | BridgeBio Pharma, Inc. |
| Ticker | NASDAQ: BBIO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | bridgebio.com |
| Employees | 725 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $73.82 | |
| Price, 1D Change | -0.61% | |
| Market Cap | $14B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.01 | |
| Revenue | $222M | |
| Revenue, 1Y Change | +2,285.27% | |
| EPS | -$2.88 | |
| EPS, 1Y Change | +27.13% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.88 | |
| EPS Estimate | -$3.19 | |
| EPS Est. Change | -10.79% | |
| Revenue | $221.90M | |
| Revenue Estimate | $495.08M | |
| Revenue Est. Change | +123.11% | |
| Current Price | $73.82 | |
| Price Target | - | $85.00 |
| Price Tgt. Change | - | +15.14% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$3.82 | -$3.95 | -3.43% | |
| -$2.39 | -$2.88 | -20.37% | |
| -$3.19 | N/A | -10.79% | |
| -$1.77 | N/A | +38.41% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $12.75M | $9.30M | -27.04% | |
| $281.76M | $221.90M | -21.24% | |
| $495.08M | N/A | +123.11% | |
| $886.85M | N/A | +299.66% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +150.66% | |
| Price, 3Y | +898.92% | |
| Market Cap, 1Y | +154.18% | |
| Market Cap, 3Y | +1,178.00% | |
| Revenue, 1Y | +2,285.27% | |
| Revenue, 3Y | +218.29% | |
| EPS, 1Y | +27.13% | |
| EPS, 3Y | +26.11% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $73.82 | |
| SMA 200 | $50.65 | |
| SMA 200 vs Price | -31.39% | |
| SMA 50 | $70.53 | |
| SMA 50 vs Price | -4.46% | |
| Beta | 1.01 | |
| ATR | $2.56 | |
| 14-Day RSI | 50.81 | |
| 10-Day Volatility | 35.87% | |
| 1-Year Volatility | 50.30% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $221.90M | |
| EPS | -$2.88 | |
| Gross Profit | $218.02M | |
| Gross Margin | 96.60% | |
| Operating Profit | -$577.37M | |
| Operating Margin | -260.19% | |
| Net Income | -$543.35M | |
| Net Margin | -244.86% | |
| EBITDA | -$436.83M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -1.51 | |
| Current Ratio | 4.67 | |
| Quick Ratio | 4.67 | |
| Interest Coverage | -4.46 | |
| F-Score | 4 | |
| Altman Z-Score | -1.73 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 40.21 | |
| PB Ratio | -7.36 | |
| EV/EBITDA | -27.62 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$1.47B | |
| Cash & Equivalents | $681.10M | |
| Total Assets | $919.34M | |
| Current Assets | $720.69M | |
| Total Liabilities | $2.38B | |
| Current Liabilities | $154.40M | |
| Total Debt | $2.21B | |
| Short Term Debt | $4.65M | |
| Accounts Payable | $9.62M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $799.27M | |
| Operating Expenses | $795.39M | |
| Cost Of Goods Sold | $7.55M | |
| SG&A | $288.93M | |
| D&A | $6.08M | |
| Interest Expense | $99.29M | |
| Income Tax | $1.15M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$520.73M | |
| CFI | $60.78M | |
| CFF | $748.46M | |
| Capex | $8.91M | |
| Free Cash Flow | -$529.63M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Leerink Partners | → | |
| Bernstein | ||
| Wells Fargo | → | |
| JP Morgan | → | |
| HC Wainwright & Co. | → | |
| Goldman Sachs | → | |
| Truist Securities | → | |
| TD Cowen | → | |
| Raymond James | → | |
| Piper Sandler | → |
Analyst sentiment
Institutional ownership
Screeners with BBIO
Data Sources & References
- BBIO Official Website bridgebio.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1743881/000174388125000012/0001743881-25-000012-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1743881/000095017025024119/0000950170-25-024119-index.htm
- BBIO Profile on Yahoo Finance finance.yahoo.com/quote/BBIO
- BBIO Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/bbio
FAQ
What is the ticker symbol for BridgeBio Pharma, Inc.?
The ticker symbol for BridgeBio Pharma, Inc. is NASDAQ:BBIO
Does BridgeBio Pharma, Inc. pay dividends?
No, BridgeBio Pharma, Inc. does not pay dividends
What sector is BridgeBio Pharma, Inc. in?
BridgeBio Pharma, Inc. is in the Healthcare sector
What industry is BridgeBio Pharma, Inc. in?
BridgeBio Pharma, Inc. is in the Biotechnology industry
What country is BridgeBio Pharma, Inc. based in?
BridgeBio Pharma, Inc. is headquartered in United States
When did BridgeBio Pharma, Inc. go public?
BridgeBio Pharma, Inc. initial public offering (IPO) was on June 27, 2019
Is BridgeBio Pharma, Inc. in the S&P 500?
No, BridgeBio Pharma, Inc. is not included in the S&P 500 index
Is BridgeBio Pharma, Inc. in the NASDAQ 100?
No, BridgeBio Pharma, Inc. is not included in the NASDAQ 100 index
Is BridgeBio Pharma, Inc. in the Dow Jones?
No, BridgeBio Pharma, Inc. is not included in the Dow Jones index
When was BridgeBio Pharma, Inc. last earnings report?
BridgeBio Pharma, Inc.'s most recent earnings report was on October 29, 2025
When does BridgeBio Pharma, Inc. report earnings?
The next expected earnings date for BridgeBio Pharma, Inc. is February 19, 2026